Allometric scaling for predicting human clearance of bisphenol A

Toxicology and Applied Pharmacology

Volumn 284, Issue 3, 2015, Pages 323-329

  Collet, Séverine H ^a,b   Picard Hagen, Nicole ^a,b   Lacroix, Marlène Z ^a,b   Puel, Sylvie ^a,b   Viguié, Catherine ^a,b   Bousquet Melou, Alain ^a,b   Toutain, Pierre Louis ^a,b   Gayrard, Véronique ^a,b  

^a CEMAGREF   (France)

^b UNIVERSITÉ DE TOULOUSE   (France)

Author keywords

Allometric scaling; Bisphenol A; Pharmacokinetics; Species invariant time

Indexed keywords

4,4' ISOPROPYLIDENEDIPHENOL; BENZHYDRYL DERIVATIVE; PHENOL DERIVATIVE; POLLUTANT;

ADMINISTRATION AND DOSAGE; ANIMAL; BILIARY EXCRETION; BIOLOGICAL MODEL; BLOOD; BODY SIZE; DOG; DOMESTIC SHEEP; FEMALE; HALF LIFE TIME; HORSE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LIVER CIRCULATION; MALE; METABOLIC CLEARANCE RATE; MOUSE; PHARMACOKINETICS; PIG; POLLUTANT; SPECIES DIFFERENCE; WISTAR RAT;

ADMINISTRATION, INTRAVENOUS; ANIMALS; BENZHYDRYL COMPOUNDS; BODY SIZE; DOGS; ENVIRONMENTAL POLLUTANTS; FEMALE; HALF-LIFE; HEPATOBILIARY ELIMINATION; HORSES; HUMANS; LIVER CIRCULATION; MALE; METABOLIC CLEARANCE RATE; MICE; MODELS, BIOLOGICAL; PHENOLS; RATS, WISTAR; SHEEP, DOMESTIC; SPECIES SPECIFICITY; SUS SCROFA;

EID: 84933509263     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2015.02.024     Document Type: Article

References (33)

1. Anantharaju A., Feller A., Chedid A. Aging liver. A review. Gerontology 2002, 48:343-353.
2. Arms A.D., Travis C.C. Reference physiological parameters in pharmacokinetic modeling 1988, Office of Health and Environmental Assessment, Office of Research and Development, U.S. Environmental Protection Agency, (EPA/600/6-88/004).
3. Bonate P.L., Howard D. Prospective allometric scaling: does the emperor have clothes?. J. Clin. Pharmacol. 2000, 40:335-340.
4. Boxenbaum H. Interspecies variation in liver weight, hepatic blood flow, and antipyrine intrinsic clearance: extrapolation of data to benzodiazepines and phenytoin. J. Pharmacokinet. Biopharm. 1980, 8:165-176.
5. Boxenbaum H., Ronfeld R. Interspecies pharmacokinetic scaling and the Dedrick plots. Am. J. Physiol. 1983, 245:R768-R75.
6. Calafat A.M., Ye X., Wong L.Y., Reidy J.A., Needham L.L. Exposure of the U.S. population to bisphenol A and 4-tertiary-octylphenol: 2003-2004. Environ. Health Perspect. 2008, 116:39-44.
7. Chappell W.R., Mordenti Y. Extrapolation of toxicological and pharmacological data from animals to humans. Adv. Drug Res. 1991, 20:1-116.
8. Cho C.Y., Shin B.S., Jung J.H., Kim D.H., Lee K.C., Han S.Y., Kim H.S., Lee B.M., Yoo S.D. Pharmacokinetic scaling of bisphenol A by species-invariant time methods. Xenobiotica 2002, 32:925-934.
9. Daneshmend T.K., Jackson L., Roberts C.J. Physiological and pharmacological variability in estimated hepatic blood flow in man. Br. J. Clin. Pharmacol. 1981, 11:491-496.
10. Dedrick R.L., Bischoff K.B., Zaharko D.S. Interspecies correlation of plasma concentration history of methotrexate (NCS-40). Cancer Chemother. Rep. 1970, Part 1(54):95-101.
11. Doerge D.R., Twaddle N.C., Woodling K.A., Fisher J.W. Pharmacokinetics of bisphenol A in neonatal and adult rhesus monkeys. Toxicol. Appl. Pharmacol. 2010, 248:1-11.
12. Doerge D.R., Twaddle N.C., Vanlandingham M., Fisher J.W. Pharmacokinetics of bisphenol A in serum and adipose tissue following intravenous administration to adult female CD-1 mice. Toxicol. Lett. 2012, 211:114-119.
13. EFSA (European Food Safety Authority) Opinion of the Scientific Panel on food additives, flavourings, processing aids and materials in contact with food (AFC) related to 2,2-bis(4-hydroxyphenyl)propane. Question number EFSA-Q-2005-100 2006, 1-75. (Available: http://www.efsa.europa.eu/EFSA/efsa_locale-1178620753812_1178620772817.htm. [accessed 4 April 2014]).
14. EFSA (European Food Safety Authority) Draft Scientific Opinion on the risks to public health related to the presence 2 of bisphenol A (BPA) in foodstuffs. On request from EFSA, Question Number EFSA-Q-2012-00423 2014, (Available: http://www.efsa.europa.eu/en/consultationsclosed/call/140117.pdf. [accessed 7 May 2014]).
15. Gayrard V., Lacroix M.Z., Collet S.H., Viguié C., Bousquet-Melou A., Toutain P.L., Picard-Hagen N. High bioavailability of bisphenol A from sublingual exposure. Environ. Health Perspect. 2013, 121:951-956.
16. Gibaldi M., Perrier D. Pharmacokinetics 1982, Marcel Dekker, New York. 2nd ed.
17. Hormann A.M., Vom Saal F.S., Nagel S.C., Stahlhut R.W., Moyer C.L., Ellersieck M.R., Welshons W.V., Toutain P.L., Taylor J.A. Holding thermal receipt paper and eating food after using hand sanitizer results in high serum bioactive and urine total levels of bisphenol A (BPA). PLoS One 2014, 9(10):e110509. 10.1371/journal.pone.0110509. eCollection 2014.
18. Huang Q., Riviere J.E. The application of allometric scaling principles to predict pharmacokinetic parameters across species. Expert. Opin. Drug Metab. Toxicol. 2014, 10:1241-1253.
19. Inoue H., Yuki G., Yokota H., Kato S. Bisphenol A glucuronidation and absorption in rat intestine. Drug Metab. Dispos. 2003, 31:140-144.
20. Lacroix M.Z., Puel S., Collet S.H., Corbel T., Picard-Hagen N., Toutain P.L., Viguié C., Gayrard V. Simultaneous quantification of bisphenol A and its glucuronide metabolite (BPA-G) in plasma and urine: applicability to toxicokinetic investigations. Talanta 2011, 85:2053-2059.
21. Lakind J.S., Naiman D.Q. Daily intake of bisphenol a and potential sources of exposure: 2005-2006 national health and nutrition examination survey. J. Exposure Sci. Environ. Epidemiol. 2011, 21:272-279.
22. Lave T., Levet-Trafit B., Schmitt-Hoffmann A.H., Morgenroth B., Richter W., Chou R.C. Interspecies scaling of interferon disposition and comparison of allometric scaling with concentration-time transformations. J. Pharm. Sci. 1995, 84:1285-1290.
23. Lipscomb J.C. Use of physiologically based pharmacokinetic models to quantify the impact of human age and interindividual differences in physiology and biochemistry pertinent to risk final report Available:. http://ofmpub.epa.gov/eims/eimscomm.getfile?p_download_id=458590.
24. Mazur C.S., Kenneke J.F., Hess-Wilson J.K., Lipscomb J.C. Differences between human and rat intestinal and hepatic bisphenol A glucuronidation and the influence of alamethicin on in vitro kinetic measurements. Drug Metab. Dispos. 2010, 38:2232-2238.
25. Mielke H., Gundert-Remy U. Bisphenol A levels in blood depend on age and exposure. Toxicol. Lett. 2009, 190:32-40.
26. Mielke H., Partosch F., Gundert-Remy U. The contribution of dermal exposure to the internal exposure of bisphenol A in man. Toxicol. Lett. 2011, 204:190-198.
27. Packard G.C., Boardman T.J. Model selection and logarithmic transformation in allometric analysis. Physiol. Biochem. Zool. 2008, 81:496-507.
28. Shin B.S., Kim C.H., Jun Y.S., Kim D.H., Lee B.M., Yoon C.H., Park E.H., Lee K.C., Han S.Y., Park K.L., Kim H.S., Yoo S.D. Physiologically based pharmacokinetics of bisphenol A. J. Toxicol. Environ. Health A 2004, 67:1971-1985.
29. Tang H., Mayerson M. A novel model for prediction of human drug clearance by allometric scaling. Drug Metab. Dispos. 2005, 33:1297-1303.
30. Taylor J.A., Vom Saal F.S., Welshons W.V., Drury B., Rottinghaus G., Hunt P.A., Toutain P.L., Laffont C.M., VandeVoort C.A. Similarity of bisphenol A pharmacokinetics in rhesus monkeys and mice: relevance for human exposure. Environ. Health Perspect. 2011, 119:422-430.
31. Vandenberg L.N., Chahoud I., Heindel J.J., Padmanabhan V., Paumgartten F.J., Schoenfelder G. Urinary, circulating, and tissue biomonitoring studies indicate widespread exposure to bisphenol A. Environ. Health Perspect. 2010, 118:1055-1070.
32. Völkel W., Colnot T., Csanady G.A., Filser J.G., Dekant W. Metabolism and kinetics of bisphenol A in humans at low doses following oral administration. Chem. Res. Toxicol. 2002, 15:1281-1287.
33. Vom Saal F.S., Prins G.S., Welshons W.V. Report of very low real-world exposure to bisphenol A is unwarranted based on a lack of data and flawed assumptions. Toxicol. Sci. 2012, 125:318-320.